Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eleanor M Riley

Showing results (151-160 of 161) with videos related to

Pageof 17
Sort By:
The New England Journal of Medicine|December 10, 2008
Efficacy of RTS,S/AS01E vaccine against malaria in children 5 to 17 months of agePhilip Bejon, John Lusingu, Ally Olotu, et al.
The Lancet. Infectious Diseases|January 18, 2011
Efficacy of RTS,S/AS01E malaria vaccine and exploratory analysis on anti-circumsporozoite antibody titres and protection in children aged 5-17 months in Kenya and Tanzania: a randomised controlled trialAlly Olotu, John Lusingu, Amanda Leach, et al.
Plos One|December 3, 2010
Safety of the malaria vaccine candidate, RTS,S/AS01E in 5 to 17 month old Kenyan and Tanzanian ChildrenJohn Lusingu, Ally Olotu, Amanda Leach, et al.
Nature Genetics|August 19, 2007
Unusual selection on the KIR3DL1/S1 natural killer cell receptor in AfricansPaul J Norman, Laurent Abi-Rached, Ketevan Gendzekhadze, et al.
Plos Medicine|October 19, 2020
The impact of delayed treatment of uncomplicated P. falciparum malaria on progression to severe malaria: A systematic review and a pooled multicentre individual-patient meta-analysisAndria Mousa, Abdullah Al-Taiar, Nicholas M Anstey, et al.
The Lancet. Infectious Diseases|September 7, 2015
Immunogenicity of the RTS,S/AS01 malaria vaccine and implications for duration of vaccine efficacy: secondary analysis of data from a phase 3 randomised controlled trialMichael T White, Robert Verity, Jamie T Griffin, et al.
Genome Research|May 5, 2009
Meiotic recombination generates rich diversity in NK cell receptor genes, alleles, and haplotypesPaul J Norman, Laurent Abi-Rached, Ketevan Gendzekhadze, et al.
Nature Communications|March 31, 2019
The temporal dynamics and infectiousness of subpatent Plasmodium falciparum infections in relation to parasite densityHannah C Slater, Amanda Ross, Ingrid Felger, et al.
Nature Communications|June 13, 2019
Author Correction: The temporal dynamics and infectiousness of subpatent Plasmodium falciparum infections in relation to parasite densityHannah C Slater, Amanda Ross, Ingrid Felger, et al.
Malaria Journal|August 29, 2015
Genetic determinants of anti-malarial acquired immunity in a large multi-centre studyJennifer M G Shelton, Patrick Corran, Paul Risley, et al.
Pageof 17

Showing results (151-160 of 161) with videos related to

Sort By:
Pageof 17
The New England Journal of Medicine|December 10, 2008
Efficacy of RTS,S/AS01E vaccine against malaria in children 5 to 17 months of agePhilip Bejon, John Lusingu, Ally Olotu, et al.
The Lancet. Infectious Diseases|January 18, 2011
Efficacy of RTS,S/AS01E malaria vaccine and exploratory analysis on anti-circumsporozoite antibody titres and protection in children aged 5-17 months in Kenya and Tanzania: a randomised controlled trialAlly Olotu, John Lusingu, Amanda Leach, et al.
Plos One|December 3, 2010
Safety of the malaria vaccine candidate, RTS,S/AS01E in 5 to 17 month old Kenyan and Tanzanian ChildrenJohn Lusingu, Ally Olotu, Amanda Leach, et al.
Nature Genetics|August 19, 2007
Unusual selection on the KIR3DL1/S1 natural killer cell receptor in AfricansPaul J Norman, Laurent Abi-Rached, Ketevan Gendzekhadze, et al.
Plos Medicine|October 19, 2020
The impact of delayed treatment of uncomplicated P. falciparum malaria on progression to severe malaria: A systematic review and a pooled multicentre individual-patient meta-analysisAndria Mousa, Abdullah Al-Taiar, Nicholas M Anstey, et al.
The Lancet. Infectious Diseases|September 7, 2015
Immunogenicity of the RTS,S/AS01 malaria vaccine and implications for duration of vaccine efficacy: secondary analysis of data from a phase 3 randomised controlled trialMichael T White, Robert Verity, Jamie T Griffin, et al.
Genome Research|May 5, 2009
Meiotic recombination generates rich diversity in NK cell receptor genes, alleles, and haplotypesPaul J Norman, Laurent Abi-Rached, Ketevan Gendzekhadze, et al.
Nature Communications|March 31, 2019
The temporal dynamics and infectiousness of subpatent Plasmodium falciparum infections in relation to parasite densityHannah C Slater, Amanda Ross, Ingrid Felger, et al.
Nature Communications|June 13, 2019
Author Correction: The temporal dynamics and infectiousness of subpatent Plasmodium falciparum infections in relation to parasite densityHannah C Slater, Amanda Ross, Ingrid Felger, et al.
Malaria Journal|August 29, 2015
Genetic determinants of anti-malarial acquired immunity in a large multi-centre studyJennifer M G Shelton, Patrick Corran, Paul Risley, et al.
Pageof 17